Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in advanced ocular VHL
NCT00673816Phase 2Terminated
- Sponsor
- National Eye Institute
- Start
- May 2008
- Primary completion
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in von Hippel-Lindau syndrome (VHL), sponsored by National Eye Institute. Primary endpoint: Best Corrected Visual Acuity at 36 weeks. Started May 2008; status: terminated.
02
Drugs
sunitinib
03
Conditions
von Hippel-Lindau syndrome (VHL)
Beyond the preview
Go deeper on NCT00673816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00673816.